HSP90AA1 and prostate carcinoma: Systemic administration of a mitochondrial-targeted, small-molecule Hsp90 inhibitor (Gamitrinib) to Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice inhibited the formation of localized prostate tumors, as well as the spread of metastatic prostate cancer to abdominal lymph nodes and liver (Kang et al. 2011).